Companies › EuBiologics
2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EuHZV Herpes zoster (shingles) vaccine | – | Phase 1 | Varicella Zoster Virus Infection | – |
| EuRSV RSV-1 and RSV-2 vaccine | – | Phase 1 | Respiratory Syncytial Virus Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06409494 | EuHZV | Phase 1 | Varicella Zoster Virus Infection | Infectious disease | Jul 2025 |
| NCT06216093 | EuRSV | Phase 1 | Respiratory Syncytial Virus Infections | Infectious disease | Jul 2025 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.